Ledermycin (Demeclocycline Hydrochloride)

Demeclocycline hydrochloride binds to the bacterial 30S ribosomal subunit, preventing the attachment of aminoacyl‑tRNA and thereby inhibiting protein synthesis. This bacteriostatic action limits bacterial growth and also interferes with antidiuretic hormone signalling in the kidneys, helping correct hyponatraemia in SIADH.

The specific dosage of Ledermycin is determined by the prescribing clinician based on the individual’s condition, severity, age, renal and hepatic function, and other relevant factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for demeclocycline in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ledermycin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ledermycin (demeclocycline) shares the core mechanism of protein synthesis inhibition with other tetracyclines but has a longer half‑life and additional activity in reducing antidiuretic hormone effects, making it useful for SIADH. Its side‑effect profile is similar, though photosensitivity and gastrointestinal upset are common across the class.

Ledermycin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas of high humidity or direct sunlight, and keep the container tightly closed when not in use.

Ledermycin is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid lying down for at least 30 minutes after ingestion to reduce the risk of oesophageal irritation.

Serious adverse events, though rare, include severe hypersensitivity reactions such as Stevens‑Johnson syndrome, hepatic toxicity, pseudotumor cerebri (increased intracranial pressure), and significant hematologic abnormalities. Patients should seek immediate medical attention if they experience rash, jaundice, persistent headache, visual changes, or unexplained bruising.

Ledermycin is contraindicated in patients with known hypersensitivity to demeclocycline or other tetracyclines, in children younger than eight years, and in pregnant or nursing women unless clearly indicated. Individuals with severe renal or hepatic impairment should also avoid use unless a specialist advises otherwise.